CLINICAL_TRIALS
trial_result
· 2022-06-27
Clinical Trial Update: The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19 [Phase 3]
Summary
Phase 3 trial comparing dexamethasone 12 mg to 6 mg in critical COVID-19 patients; focused on thromboembolic events as outcomes.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Karolinska Institutet | Conditions: COVID-19, Thrombosis Embolism | Phase 3 | Status: COMPLETED